Assuntos
Hamartoma/congênito , Extremidade Inferior/patologia , Músculo Liso/patologia , Dor/etiologia , Pré-Escolar , Diagnóstico Diferencial , Hamartoma/diagnóstico , Hamartoma/metabolismo , Humanos , Hiperpigmentação/diagnóstico , Hiperpigmentação/metabolismo , Hiperpigmentação/patologia , Masculino , Dor/diagnóstico , Dermatopatias/patologiaAssuntos
Eosinofilia/patologia , Foliculite/patologia , Couro Cabeludo/patologia , Dermatopatias Vesiculobolhosas/patologia , Dermatopatias/patologia , Anti-Infecciosos/administração & dosagem , Anti-Infecciosos/uso terapêutico , Dapsona/administração & dosagem , Dapsona/uso terapêutico , Diagnóstico Diferencial , Eosinofilia/imunologia , Foliculite/imunologia , Glucocorticoides/administração & dosagem , Glucocorticoides/uso terapêutico , Humanos , Lactente , Masculino , Prednisolona/administração & dosagem , Prednisolona/uso terapêutico , Couro Cabeludo/imunologia , Dermatopatias/imunologia , Dermatopatias Vesiculobolhosas/imunologia , Resultado do TratamentoRESUMO
Many studies have found that screening and treatment of latent tuberculosis (TB) before starting treatment with tumour necrosis factor (TNF)-a inhibitors reduces associated TB infections. The new T-cell interferon-a release assay (TIGRA), is more specific and sensitive for detection of latent TB compared with the tuberculin skin test (TST). We report results of TIGRA in our first 63 patients commencing TNF-a inhibitors for severe psoriasis. Of the 63 patients, 5 (7.9%) had a positive TIGRA result and were started on treatment for latent TB. We found that the only risk factor for TB associated with a positive TIGRA was a history of travel to countries with high TB incidence. To our knowledge, this is the first study to identify the background risk (7.9%) of latent TB in an endemic UK population. This result emphasizes the importance of TIGRA testing to reduce the risk of TB in patients treated with TNF-a inhibitor.
Assuntos
Interferon-alfa/análise , Tuberculose Latente/diagnóstico , Psoríase/tratamento farmacológico , Linfócitos T/imunologia , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Adolescente , Adulto , Idoso , Feminino , Humanos , Imunossupressores/efeitos adversos , Interferon-alfa/metabolismo , Tuberculose Latente/imunologia , Masculino , Programas de Rastreamento/métodos , Pessoa de Meia-Idade , Mycobacterium tuberculosis , Psoríase/imunologia , Fatores de Risco , Índice de Gravidade de Doença , Viagem , Teste Tuberculínico/métodos , Reino Unido , Adulto JovemRESUMO
Giant congenital melanocytic naevi remain a challenge to clinicians and histopathologists with respect to observation for malignant change and interpretation of histology findings, respectively. We report a 5-year-old boy with a giant bathing trunk naevus who, after multiple previous skin biopsies, developed lymphadenopathy. Biopsy from the lymph nodes demonstrated collections of naevomelanocytes within the lymph node. Interpretation of these findings and subsequent management is discussed.
Assuntos
Nevo Pigmentado/patologia , Neoplasias Cutâneas/patologia , Transformação Celular Neoplásica , Pré-Escolar , Humanos , Metástase Linfática/patologia , Masculino , Nevo Pigmentado/congênito , Neoplasias Cutâneas/congênitoRESUMO
Myrmecia are viral warts that result from the coalescence of plantar or palmar warts into large plaques. Treatment of these warts involves physical or chemical destruction of the verrucae, potent keratolytics or immunotherapy. Imiquimod 5% cream is a novel topical immunomodulator that has been used successfully in the treatment of genital and common warts. We report its successful use in a 35-year-old immunocompetent man who had had resistant plantar warts for 15 years.
